Sundry Photography/iStock Editorial via Getty Images 10x Genomics ( NASDAQ: TXG ) reported preliminary third quarter revenue of $151.7M on Wednesday, representing an approximate 1% decrease from the corresponding prior year period. The company reported preliminary cash and cash equivalents of approximately $398M as of September 30, 2024.
10x.
